Highlights
Case study: Fast, quantitative SPECT/CT acquisition following multiple therapy cycles of 177Lu-PSMA-617
This clinical case demonstrates how Symbia Intevo Bold™ with xSPECT Quant™ enables 177Lu-PSMA-617 treatment response assessment.
Scientific presentation:
Empowering precision oncology - Expanding access to next-generation theranostics
Joseph R. Osborne, MD, PhD; Chief, Division of Molecular Imaging and Therapeutics, Professor of Radiology, Weill Cornell Medicine, New York, New York.
Scientific presentation: Clinical experience of routine SPECT/CT reading after migrating from Symbia.net to syngo.via
Iain Duncan, MD, Garran Medical Imaging, Canberra, Australia
Case study: Fast, quantitative SPECT/CT acquisition following multiple therapy cycles of 177Lu-PSMA-617
This clinical case demonstrates how Symbia Intevo Bold™ with xSPECT Quant™ enables 177Lu-PSMA-617 treatment response assessment.
Scientific presentation:
Empowering precision oncology - Expanding access to next-generation theranostics
Joseph R. Osborne, MD, PhD; Chief, Division of Molecular Imaging and Therapeutics, Professor of Radiology, Weill Cornell Medicine, New York, New York.
Scientific presentation: Clinical experience of routine SPECT/CT reading after migrating from Symbia.net to syngo.via
Iain Duncan, MD, Garran Medical Imaging, Canberra, Australia
Case study: Fast, quantitative SPECT/CT acquisition following multiple therapy cycles of 177Lu-PSMA-617
This clinical case demonstrates how Symbia Intevo Bold™ with xSPECT Quant™ enables 177Lu-PSMA-617 treatment response assessment.